ANI Pharmaceuticals (NASDAQ:ANIP) Raised to Sell at BidaskClub

BidaskClub upgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a strong sell rating to a sell rating in a research report report published on Saturday morning, BidAskClub reports.

A number of other research firms also recently commented on ANIP. ValuEngine downgraded shares of ANI Pharmaceuticals from a hold rating to a sell rating in a report on Thursday, April 30th. Cantor Fitzgerald downgraded shares of ANI Pharmaceuticals from an overweight rating to a neutral rating and dropped their target price for the stock from $78.00 to $40.00 in a report on Thursday, May 7th. Guggenheim cut their price target on shares of ANI Pharmaceuticals from $62.00 to $58.00 and set a buy rating on the stock in a report on Thursday, April 30th. Raymond James cut their price target on shares of ANI Pharmaceuticals from $65.00 to $49.00 and set an outperform rating on the stock in a report on Friday, May 8th. Finally, Zacks Investment Research lowered shares of ANI Pharmaceuticals from a hold rating to a sell rating in a report on Wednesday, May 27th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus target price of $46.50.

NASDAQ ANIP opened at $32.34 on Friday. The company has a debt-to-equity ratio of 0.93, a current ratio of 2.00 and a quick ratio of 1.33. The company’s 50 day simple moving average is $31.32 and its 200 day simple moving average is $46.70. ANI Pharmaceuticals has a 12 month low of $28.28 and a 12 month high of $86.96. The company has a market capitalization of $368.87 million, a P/E ratio of -215.59 and a beta of 1.46.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.04 EPS for the quarter, topping analysts’ consensus estimates of $0.89 by $0.15. ANI Pharmaceuticals had a negative net margin of 0.67% and a positive return on equity of 23.92%. The business had revenue of $49.77 million for the quarter, compared to the consensus estimate of $49.40 million. On average, analysts anticipate that ANI Pharmaceuticals will post 3.84 earnings per share for the current year.

Institutional investors have recently added to or reduced their stakes in the business. Advisor Group Holdings Inc. acquired a new position in ANI Pharmaceuticals in the 1st quarter valued at approximately $42,000. Sowell Financial Services LLC increased its stake in ANI Pharmaceuticals by 15,300.0% in the 1st quarter. Sowell Financial Services LLC now owns 1,232 shares of the specialty pharmaceutical company’s stock valued at $50,000 after buying an additional 1,224 shares during the period. Truvestments Capital LLC acquired a new position in ANI Pharmaceuticals in the 1st quarter valued at approximately $64,000. Meeder Asset Management Inc. increased its stake in ANI Pharmaceuticals by 9,900.0% in the 4th quarter. Meeder Asset Management Inc. now owns 2,000 shares of the specialty pharmaceutical company’s stock valued at $125,000 after buying an additional 1,980 shares during the period. Finally, BNP Paribas Arbitrage SA increased its stake in ANI Pharmaceuticals by 77.1% in the 1st quarter. BNP Paribas Arbitrage SA now owns 3,658 shares of the specialty pharmaceutical company’s stock valued at $149,000 after buying an additional 1,593 shares during the period. Hedge funds and other institutional investors own 65.65% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

Recommended Story: What factors cause inflation to rise?

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.